Sections SEARCH Skip to content Skip to site index Health Subscribe Log In Subscribe Log In Today’s Paper Advertisement Supported by ByDenise Grady Oct. 1, 2018 The Nobel Prize in Physiology or Medicine was awarded on Monday to James P. Allison of the United States and Tasuku Honjo of Japan for their work on unleashing the body’s immune system to attack cancer, a breakthrough that has led to an entirely new class of drugs and brought lasting remissions to many patients who had run out of options. Their success, which came after many researchers had given up on the idea, “brought immunotherapy out from decades of skepticism,” said Dr. Jedd Wolchok, a cancer specialist at Memorial Sloan Kettering Cancer Center in New York. It has, he said, “led to human applications that have affected an untold number of people’s health.” Before Dr. Allison’s and Dr. Honjo’s discoveries, cancer … [Read more...] about 2018 Nobel Prize in Medicine Awarded to 2 Cancer Immunotherapy Researchers
Lung cancer where does it spread
Video PUBLISHED: 13:15 19 September 2018 | UPDATED: 14:11 19 September 2018 Steve Russell John Travolta and Olivia Newton-John in Grease Picture: UIP How old do you think Olivia Newton-John will be next week? We look at her life and career: from East Anglia to Eurovision and Grease, and her fight with cancer Olivia Newton-John in 1994 Picture: Stefan Rousseau/PA“Oh, she had a good pair of lungs on her as a baby,” says my mother, back in 1978, as Grease-mania grips Britain. Who? “Olivia Newton-John.” What? Okaaay… How do you know? “Well, I saw her. Her dad was a headmaster in Cambridge.”Tantalising. And, unfortunately, pretty much all. I didn’t pursue it then (big mistake) and my mother’s no longer here to ask.Olivia Newton-John was born in Cambridge in 1948 (yep, she’s not an Australian, as almost everyone seems to think). It was a couple of years or so after … [Read more...] about Why does hardly anyone know where Olivia Newton-John was born?!
Patricia Ansett Published 8:20 p.m. UTC Aug 22, 2018 Aretha Franklin’s diagnosis and death from pancreatic cancer is likely to provide better insight into who gets it and why. Here are the answers to some frequently asked questions about it: How common is pancreatic cancer? Pancreatic cancer accounts for only 3.2 percent of all cancers, and 7.2 percent of all cancer deaths, according to the American Cancer Society. An estimated 55,440 people (29,200 men and 26,240 women) will be diagnosed with pancreatic cancer in 2018 in the United States. In Michigan, an estimated new 1,920 cases will be diagnosed in 2018, and 1,610 people will die of it, according to the cancer society. Who gets pancreatic cancer? It is more common in African-Americans, as well as all men, for reasons that are not well known. Though it affects people in middle age, it is mostly a disease of aging, with risk of getting it increasing at 55. The median age of diagnosis is 70. It is … [Read more...] about Aretha Franklin death: Common questions about pancreatic cancer
Taking a drug from idea to an actual treatment takes many years of research and costs hundreds of millions of dollars. For every drug that wins approval from the Food and Drug Administration, thousands of experimental compounds fail in testing to prove safe and effective, or never even make it that far Researchers on that journey from lab to bedside at Williamsville-based For-Robin Inc. hope their work will lead to a new therapy for breast cancer and other tumors. Success could be lucrative, too. It's a long slog, but the University at Buffalo spinoff recently received a crucial boost from the National Cancer Institute, which selected the company to join its experimental therapeutics program to help accelerate promising treatments into clinical trials in humans. "It's exciting because this gets us where we want to be," said Kate Rittenhouse-Olson, president and chief science officer. "We competed against big and small companies, and only 10 percent or fewer are selected." The National … [Read more...] about A scientist’s personal journey to commercialize a cancer drug
The U.S. Preventative Services Task Force has recently updated and modified its controversial 2012 recommendation to abandon routine screening of all men using the prostate cancer screening blood test called the prostate specific antigen or PSA test. The USPSTF is a government task force comprised of members from the fields of primary care and preventive medicine that currently makes evidence-based recommendations about clinical preventive services. The updated recommendation is that all U.S. men between the ages of 55 to 69 should consider PSA screening, after discussing the risks and benefits with their doctor. The panel recommended that men older than 70 should not undergo screening.MORE HEALTH: In praise of stay safe rules: Memories from a 'free-range' childhoodThe 2012 recommendation was of great concern to physicians who treat prostate cancer, survivors of the disease, and those at high risk due to race or hereditary factors. As a urologist who treats and has cared for … [Read more...] about Prostate cancer screening: An expert explains why new guidelines were needed